http://www.wjnm.org/currentissue.asp World J Nucl Med 2011 - 10(2) World Journal of Nuclear Medicine Medknow Publications1450-1147 Ajit Kumar Padhy Editorial World Journal of Nuclear Medicine 2011 10(2):111-112doi:10.4103/1450-1147.89773 World Journal of Nuclear Medicine 10.4103/1450-1147.89773 http://www.wjnm.org/text.asp?2011/10/2/111/89773 http://www.wjnm.org/text.asp?2011/10/2/111/89773102 111 112 http://www.wjnm.org/text.asp?2011/10/2/111/89773 Ajit Kumar Padhy

World Journal of Nuclear Medicine 2011 10(2):111-112

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/111/89773 Hee-Seung Bom June-Key Chung Myung-Chul Lee Commentary World Journal of Nuclear Medicine 2011 10(2):113-114doi:10.4103/1450-1147.89777 World Journal of Nuclear Medicine 10.4103/1450-1147.89777 http://www.wjnm.org/text.asp?2011/10/2/113/89777 http://www.wjnm.org/text.asp?2011/10/2/113/89777102 113 114 http://www.wjnm.org/text.asp?2011/10/2/113/89777 Hee-Seung Bom, June-Key Chung, Myung-Chul Lee

World Journal of Nuclear Medicine 2011 10(2):113-114

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/113/89777 T Traub-Weidinger M Raderer M Uffmann P Angelberger A Kurtaran M Leimer J Preitfellner R Dudczak I Virgolini Original Article World Journal of Nuclear Medicine 2011 10(2):115-121doi:10.4103/1450-1147.89779 World Journal of Nuclear Medicine 10.4103/1450-1147.89779 http://www.wjnm.org/text.asp?2011/10/2/115/89779 http://www.wjnm.org/text.asp?2011/10/2/115/89779102 115 121 http://www.wjnm.org/text.asp?2011/10/2/115/89779 T Traub-Weidinger, M Raderer, M Uffmann, P Angelberger, A Kurtaran, M Leimer, J Preitfellner, R Dudczak, I Virgolini

World Journal of Nuclear Medicine 2011 10(2):115-121

Peptide receptor radionuclide therapy (PRRT) has recently been established as an important treatment modality for somatostatin receptor (SSTR)-positive tumors. The purpose of this study was to evaluate the clinical response, side-effects as well as the quality of life following 90 Y-DOTA-lanreotide (DOTALAN) and/or 90 Y-DOTA-Tyr 3 -DPhe 1 -octreotide (DOTATOC) therapy in patients with progressive metastatic disease during a 6-year follow-up period. Following dosimetric evaluation with 111 In-DOTALAN and 111 In-DOTATOC, 13 patients with estimated absorbed tumor doses of >5 Gy/GBq (carcinoid, n = 5; radioiodine-negative thyroid cancer, n = 4; gastrinoma, n = 1; insulinoma, n = 1; glucagonoma, n = 1; glomus jugularis tumor, n = 1) were assigned for PRRT. A dose of 925 MBq of 90 Y-DOTALAN (four patients) or 1.85-3.7 GBq of 90 Y-DOTATOC (10 patients) was administered intravenously and repeated every 4-8 weeks. Tumor dosimetry was performed prior to and under therapy, re-staging every 2-3 months. Pain intensity, Karnofsky score and general symptoms were evaluated in order to determine quality of life. Patients were followed until death. Altogether, 53 infusions of PRRT (1.85-14.1 GBq) were administered. After the first follow-up of 3 months of 90 Y-DOTALAN therapy, stable disease (SD) was observed in one patient and progressive disease (PD) in three patients. With 90 Y-DOTATOC therapy, SD was found in all 10 patients. During the re-evaluation period (4-27 months), one patient had to be shifted from 90 Y-DOTALAN to 90 Y-DOTATOC therapy due to reduced 111 In-DOTALAN uptake after 5.5 GBq. In the first 6 months after PRRT with DOTATOC, SD was found in nine of 10 patients and PD in one patient. Thereafter, SD was observed in two patients and PD in eight patients. Nine of 13 patients after PRRT with either DOTALAN or DOTATOC died. None of the patients had experienced severe acute hematological side-effects. Transient thrombocytopenia or lymphocytopenia was seen in 10 patients after 3.7 GBq, and a skin reaction in one patient. Total accumulated kidney dose ranged between 4 and 64 Gy, with reduced creatinine clearance in two patients. Pain relief was achieved in three of three patients after ~3.7 GBq ERT within 4-6 months. Appetite, weight, Karnofsky score and general well-being had improved in patients with SD during and after therapy. Based on the results of this study conducted on a small group of patients, we conclude that PRRT may offer an alternative treatment option for SSTR-positive tumors, with only mild transient side-effects and a marked improvement in the quality of life.]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/115/89779 Kelvin S.H Loke Ajit K Padhy David C.E Ng Anthony S.W Goh Chaitanya Divgi Dosimetry World Journal of Nuclear Medicine 2011 10(2):122-138doi:10.4103/1450-1147.89780 World Journal of Nuclear Medicine 10.4103/1450-1147.89780 http://www.wjnm.org/text.asp?2011/10/2/122/89780 http://www.wjnm.org/text.asp?2011/10/2/122/89780102 122 138 http://www.wjnm.org/text.asp?2011/10/2/122/89780 Kelvin S.H Loke, Ajit K Padhy, David C.E Ng, Anthony S.W Goh, Chaitanya Divgi

World Journal of Nuclear Medicine 2011 10(2):122-138

Radiopharmaceutical therapy, once touted as the "magic bullet" in radiation oncology, is increasingly being used in the treatment of a variety of malignancies; albeit in later disease stages. With ever-increasing public and medical awareness of radiation effects, radiation dosimetry is becoming more important. Dosimetry allows administration of the maximum tolerated radiation dose to the tumor/organ to be treated but limiting radiation to critical organs. Traditional tumor dosimetry involved acquiring pretherapy planar scans and plasma estimates with a diagnostic dose of intended radiopharmaceuticals. New advancements in single photon emission computed tomography and positron emission tomography systems allow semi-quantitative measurements of radiation dosimetry thus allowing treatments tailored to each individual patient.]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/122/89780 SP Thang A. E. H Tan A. S. W Goh Case Report World Journal of Nuclear Medicine 2011 10(2):139-140doi:10.4103/1450-1147.89782 World Journal of Nuclear Medicine 10.4103/1450-1147.89782 http://www.wjnm.org/text.asp?2011/10/2/139/89782 http://www.wjnm.org/text.asp?2011/10/2/139/89782102 139 140 http://www.wjnm.org/text.asp?2011/10/2/139/89782 SP Thang, A. E. H Tan, A. S. W Goh

World Journal of Nuclear Medicine 2011 10(2):139-140

Findings of a solitary "hot spot" at the superior lateral orbital margin on bone scan scintigraphy is not uncommonly seen, and is often dismissed as a benign lesion. However, the exact etiology is indeterminate. We present two cases in which hybrid single photon emission computed tomography/computed tomography imaging was able to characterize and localize this uptake, demonstrating correlation to the right fronto-zygomatic suture.]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/139/89782 Abstracts World Journal of Nuclear Medicine 2011 10(2):141-141World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/141/89783 http://www.wjnm.org/text.asp?2011/10/2/141/89783102 141 141 http://www.wjnm.org/text.asp?2011/10/2/141/89783

World Journal of Nuclear Medicine 2011 10(2):141-141

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/141/89783 Abstract World Journal of Nuclear Medicine 2011 10(2):142-177World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/142/89784 http://www.wjnm.org/text.asp?2011/10/2/142/89784102 142 177 http://www.wjnm.org/text.asp?2011/10/2/142/89784

World Journal of Nuclear Medicine 2011 10(2):142-177

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/142/89784 Abstract World Journal of Nuclear Medicine 2011 10(2):178-189World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/178/89785 http://www.wjnm.org/text.asp?2011/10/2/178/89785102 178 189 http://www.wjnm.org/text.asp?2011/10/2/178/89785

World Journal of Nuclear Medicine 2011 10(2):178-189

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/178/89785 Abstracts World Journal of Nuclear Medicine 2011 10(2):190-209World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/190/89787 http://www.wjnm.org/text.asp?2011/10/2/190/89787102 190 209 http://www.wjnm.org/text.asp?2011/10/2/190/89787

World Journal of Nuclear Medicine 2011 10(2):190-209

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/190/89787 Abstracts World Journal of Nuclear Medicine 2011 10(2):210-215World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/210/89788 http://www.wjnm.org/text.asp?2011/10/2/210/89788102 210 215 http://www.wjnm.org/text.asp?2011/10/2/210/89788

World Journal of Nuclear Medicine 2011 10(2):210-215

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/210/89788 Abstracts World Journal of Nuclear Medicine 2011 10(2):216-225World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/216/89789 http://www.wjnm.org/text.asp?2011/10/2/216/89789102 216 225 http://www.wjnm.org/text.asp?2011/10/2/216/89789

World Journal of Nuclear Medicine 2011 10(2):216-225

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/216/89789 Abstracts World Journal of Nuclear Medicine 2011 10(2):226-245World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/226/89790 http://www.wjnm.org/text.asp?2011/10/2/226/89790102 226 245 http://www.wjnm.org/text.asp?2011/10/2/226/89790

World Journal of Nuclear Medicine 2011 10(2):226-245

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/226/89790 Abstracts World Journal of Nuclear Medicine 2011 10(2):246-248World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2011/10/2/246/89791 http://www.wjnm.org/text.asp?2011/10/2/246/89791102 246 248 http://www.wjnm.org/text.asp?2011/10/2/246/89791

World Journal of Nuclear Medicine 2011 10(2):246-248

]]> Sat,12 Nov 2011http://www.wjnm.org/text.asp?2011/10/2/246/89791